Shakshuki Ayah, Agu Remigius U
Biopharmaceutics and Drug Delivery Lab, College of Pharmacy, Halifax, Canada.
Pulm Ther. 2017 Dec;3(2):267-281. doi: 10.1007/s41030-017-0046-2. Epub 2017 Jun 27.
Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous airway diseases associated with significant morbidity and mortality. Pharmacological treatment is delivered primarily through the inhalation route using various devices. Optimal disease control is highly dependent upon patient adherence. Both patients with asthma and COPD are prone to exacerbations leading to hospitalization, which can significantly impact quality of life. Poor adherence is a complex and multifactorial problem that does not have one simple solution. However, it is the biggest risk factor for exacerbations and consequently high healthcare utilization. This review discusses the complex and multifactorial obstacles that impact patient adherence as well as the effect on overall treatment outcomes and healthcare utilization. We also critically examined and compared relatively recent improvements in breath-activated pressurized metered dose inhalers, dry powder inhalers, and e-technology in asthma and COPD. Finally, future treatment strategies for better patient compliance such as personalized medicine and the importance of decision-making between patients and physicians were highlighted.
哮喘和慢性阻塞性肺疾病(COPD)是异质性气道疾病,与显著的发病率和死亡率相关。药物治疗主要通过使用各种装置经吸入途径给药。最佳疾病控制高度依赖于患者的依从性。哮喘和COPD患者都容易出现导致住院的病情加重,这会显著影响生活质量。依从性差是一个复杂的多因素问题,没有一个简单的解决方案。然而,它是病情加重以及因此导致高医疗利用率的最大风险因素。本综述讨论了影响患者依从性的复杂多因素障碍以及对总体治疗结果和医疗利用率的影响。我们还严格审查并比较了呼吸启动压力定量吸入器、干粉吸入器和电子技术在哮喘和COPD方面相对较新的改进。最后,强调了改善患者依从性的未来治疗策略,如个性化医疗以及患者与医生之间决策的重要性。